A Phase Ib/II, open-label, multicenter, randomized clinical trial to evaluate atezolizumab in combination with PEGPH20 in the treatment metastatic pancreatic ductal adenocarcinoma.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 May 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

07 May 2020 According to a Roche media release, data from this trial will be presented at the will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO), which will be held 29-31 May, 2020.
13 Jul 2017 Status changed from planning to recruiting, according to a Halozyme Therapeutics media release.
28 Nov 2016 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com